Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Stage IV Rectal Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Stage IV Rectal Cancer cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
Eniluracil
National Cancer Institute (NCI)
Phase 3BB
Dasatinib
Anne Noonan
Phase 2B
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B

View all 26 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →